3681 — Sinomab Bioscience Share Price
Last trade - 00:00- HK$1.98bn
- HK$2.21bn
- CNY1.37m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.17 | ||
| Price to Tang. Book | 6.21 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,336.74 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -35.03% | ||
| Return on Equity | -60.39% | ||
| Operating Margin | -17327.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | 25.91 | n/a | 1.36 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SinoMab BioScience Ltd is a Hong Kong-based biopharmaceutical company mainly dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company primarily develops mAb-based biologics and new chemical entities (NCE). The Company’s product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The Company is developing drugs for the treatment of RA, systemic lupus erythematosus (SLE), asthma, pemphigus, sjogren’s syndrome (SS) and other immunological diseases.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 27th, 2001
- Public Since
- November 12th, 2019
- No. of Employees
- 233
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,091,755,119
- Address
- 22/F
- Web
- https://www.sinomab.com/
- Phone
- +852 null34269833
- Auditors
- Ernst & Young
Upcoming Events for 3681
Similar to 3681
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:20 UTC, shares in Sinomab Bioscience are trading at HK$1.81. This share price information is delayed by 15 minutes.
Shares in Sinomab Bioscience last closed at HK$1.81 and the price had moved by -2.69% over the past 365 days. In terms of relative price strength the Sinomab Bioscience share price has underperformed the FTSE Developed Asia Pacific Index by -2.02% over the past year.
There is no consensus recommendation for this security.
Sinomab Bioscience does not currently pay a dividend.
Sinomab Bioscience does not currently pay a dividend.
Sinomab Bioscience does not currently pay a dividend.
To buy shares in Sinomab Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$1.81, shares in Sinomab Bioscience had a market capitalisation of HK$1.98bn.
Here are the trading details for Sinomab Bioscience:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 3681
Based on an overall assessment of its quality, value and momentum Sinomab Bioscience is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sinomab Bioscience. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +50.58%.
As of the last closing price of HK$1.81, shares in Sinomab Bioscience were trading +27.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sinomab Bioscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$1.81.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Sinomab Bioscience's directors